Literature DB >> 8734833

A population-based study of contralateral breast cancer following a first primary breast cancer (Washington, United States)

L S Cook1, E White, S M Schwartz, B McKnight, J R Daling, N S Weiss.   

Abstract

To evaluate predictors of contralateral breast cancer risk, we examined data from a nested case-control study of second primary cancers among a cohort of women in western Washington (United States) diagnosed with breast cancer during 1978 through 1990 and identified through a population-based cancer registry. Cases included all women in the cohort who subsequently developed contralateral breast cancer at least six months after the initial diagnosis, but prior to 1992 (n = 234). Controls were sampled randomly from the cohort, matched to cases on age, stage, and year of initial breast cancer diagnosis. Information on potential risk factors for second primary cancer was obtained through medical record abstractions and physician questionnaires. Women who were postmenopausal due to a bilateral oophorectomy (i.e., a surgical menopause) at initial breast cancer diagnosis had a reduction in contralateral breast cancer risk compared with premenopausal women (matched odds ratio [mOR] = 0.25, 95 percent confidence interval [CI] = 0.09-0.68), whereas no reduction in risk was noted among postmenopausal women who had had a natural menopause (mOR = 0.90, CI = 0.39-2.09). Among postmenopausal women, there was a suggestion of a lower risk associated with relatively high parity (2+). A family history of breast cancer was associated with an increased risk (mOR = 1.96, CI = 1.22-5.15) and varied little by menopausal status. Having an initial tumor with a lobular component (c.f. a ductal histology) was not related strongly to risk (mOR = 1.47, CI = 0.79-2.74). The results of the present and earlier studies argue that we have limited ability to predict the occurrence of a contralateral breast tumor. Better predictors will be required before diagnostic and preventive interventions can be targeted to subgroups of patients with unilateral breast cancer.

Entities:  

Mesh:

Year:  1996        PMID: 8734833     DOI: 10.1007/bf00052945

Source DB:  PubMed          Journal:  Cancer Causes Control        ISSN: 0957-5243            Impact factor:   2.506


  32 in total

1.  Adjuvant chemotherapy in early breast cancer and incidence of new primary malignancies.

Authors:  R Arriagada; L E Rutqvist
Journal:  Lancet       Date:  1991-08-31       Impact factor: 79.321

Review 2.  Diet, body size, and breast cancer.

Authors:  D J Hunter; W C Willett
Journal:  Epidemiol Rev       Date:  1993       Impact factor: 6.222

Review 3.  Reproductive factors and breast cancer.

Authors:  J L Kelsey; M D Gammon; E M John
Journal:  Epidemiol Rev       Date:  1993       Impact factor: 6.222

4.  A retrospective cohort analysis of second breast cancer risk for primary breast cancer patients with an assessment of the effect of radiation therapy.

Authors:  B F Hankey; R E Curtis; M D Naughton; J D Boice; J T Flannery
Journal:  J Natl Cancer Inst       Date:  1983-05       Impact factor: 13.506

5.  Risk of breast cancer among young women: relationship to induced abortion.

Authors:  J R Daling; K E Malone; L F Voigt; E White; N S Weiss
Journal:  J Natl Cancer Inst       Date:  1994-11-02       Impact factor: 13.506

6.  Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy. 133 randomised trials involving 31,000 recurrences and 24,000 deaths among 75,000 women. Early Breast Cancer Trialists' Collaborative Group.

Authors: 
Journal:  Lancet       Date:  1992-01-11       Impact factor: 79.321

7.  A comprehensive evaluation of family history and breast cancer risk. The Utah Population Database.

Authors:  M L Slattery; R A Kerber
Journal:  JAMA       Date:  1993-10-06       Impact factor: 56.272

8.  Population-based study of tamoxifen therapy and subsequent ovarian, endometrial, and breast cancers.

Authors:  L S Cook; N S Weiss; S M Schwartz; E White; B McKnight; D E Moore; J R Daling
Journal:  J Natl Cancer Inst       Date:  1995-09-20       Impact factor: 13.506

9.  Second primary cancers following female breast cancer in Osaka, Japan--a population-based cohort study.

Authors:  R Murakami; T Hiyama; A Hanai; I Fujimoto
Journal:  Jpn J Clin Oncol       Date:  1987-12       Impact factor: 3.019

10.  Risk of contralateral breast cancer. Associations with histologic, clinical, and therapeutic factors.

Authors:  P L Horn; W D Thompson
Journal:  Cancer       Date:  1988-07-15       Impact factor: 6.860

View more
  12 in total

1.  Cancer registries in epidemiologic research.

Authors:  H H Storm
Journal:  Cancer Causes Control       Date:  1996-05       Impact factor: 2.506

2.  Outcomes of classic lobular neoplasia diagnosed on breast core needle biopsy: a retrospective multi-center study.

Authors:  Iskender Sinan Genco; Bugra Tugertimur; Qing Chang; Lauren Cassell; Sabina Hajiyeva
Journal:  Virchows Arch       Date:  2019-11-27       Impact factor: 4.064

3.  A case report of male breast cancer in a very young patient: what is changing?

Authors:  Marcelo Madeira; André Mattar; Rodrigo José Barata Passos; Caroline Dornelles Mora; Luiz Henrique Beralde Vilar Mamede; Viviane Hatsumi Kishino; Thomas Zurga Markus Torres; Andressa Fernandes Rodrigues de Sá; Roberto Euzébio dos Santos; Luiz Henrique Gebrim
Journal:  World J Surg Oncol       Date:  2011-02-03       Impact factor: 2.754

4.  Adjuvant systemic therapy for breast cancer in BRCA1/BRCA2 mutation carriers in a population-based study of risk of contralateral breast cancer.

Authors:  Kerryn W Reding; Jonine L Bernstein; Bryan M Langholz; Leslie Bernstein; Robert W Haile; Colin B Begg; Charles F Lynch; Patrick Concannon; Ake Borg; Sharon N Teraoka; Therese Törngren; Anh Diep; Shanyan Xue; Lisbeth Bertelsen; Xiaolin Liang; Anne S Reiner; Marinela Capanu; Kathleen E Malone
Journal:  Breast Cancer Res Treat       Date:  2010-02-05       Impact factor: 4.872

5.  Reproductive factors and risk of contralateral breast cancer by BRCA1 and BRCA2 mutation status: results from the WECARE study.

Authors:  Jenny N Poynter; Bryan Langholz; Joan Largent; Lene Mellemkjaer; Leslie Bernstein; Kathleen E Malone; Charles F Lynch; Ake Borg; Patrick Concannon; Sharon N Teraoka; Shanyan Xue; Anh T Diep; Therese Törngren; Colin B Begg; Marinela Capanu; Robert W Haile; Jonine L Bernstein
Journal:  Cancer Causes Control       Date:  2010-02-04       Impact factor: 2.506

6.  Histo-biological comparative analysis of bilateral breast cancer.

Authors:  Bilal Baker; Basem Morcos; Faiez Daoud; Maher Sughayer; Maher Sughayyer; Hisham Shabani; Habeeb Salameh; Mahmoud Almasri
Journal:  Med Oncol       Date:  2013-09-24       Impact factor: 3.064

7.  A model for individualized risk prediction of contralateral breast cancer.

Authors:  Marzana Chowdhury; David Euhus; Tracy Onega; Swati Biswas; Pankaj K Choudhary
Journal:  Breast Cancer Res Treat       Date:  2016-11-04       Impact factor: 4.624

8.  Systemic therapy for breast cancer and risk of subsequent contralateral breast cancer in the WECARE Study.

Authors:  Rikke Langballe; Lene Mellemkjær; Kathleen E Malone; Charles F Lynch; Esther M John; Julia A Knight; Leslie Bernstein; Jennifer Brooks; Michael Andersson; Anne S Reiner; Xiaolin Liang; Meghan Woods; Patrick J Concannon; Jonine L Bernstein
Journal:  Breast Cancer Res       Date:  2016-07-12       Impact factor: 6.466

9.  Relation of risk of contralateral breast cancer to the interval since the first primary tumour.

Authors:  C Rubino; R Arriagada; S Delaloge; M G Lê
Journal:  Br J Cancer       Date:  2009-11-17       Impact factor: 7.640

10.  Second malignancies following conventional or combined ²⁵²Cf neutron brachytherapy with external beam radiotherapy for breast cancer.

Authors:  Konstantinas Povilas Valuckas; Vydmantas Atkocius; Irena Kuzmickiene; Eduardas Aleknavicius; Sarune Liukpetryte; Valerijus Ostapenko
Journal:  J Radiat Res       Date:  2013-02-07       Impact factor: 2.724

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.